Amylyx Pharmaceuticals(us:AMLX)
3.43
-2.28%
Updated on 2025-04-04
Open:3.32
Close:3.43
High:3.56
Low:3.32
Prev Close:3.51
Volume:914162.00
Turnover:3.13M
Turnover Ratio:1.03%
Shares:88.60M
MarketCap:303.91M
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Company Name: Amylyx Pharmaceuticals
Address: 43 Thorndike Street
Employees: 384
Fiscar Year: 12-31
IPO Date: 2022-01-07
Website: http://www.amylyx.com
CIK: 1658551
View all SEC Filings
About
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Address:43 Thorndike Street
Website:http://www.amylyx.com
Market Movers